Leap therapeutics announces completion of enrollment in randomized controlled part c of the distinguish study of dkn-01 for the treatment of gastric cancer patients

Cambridge, mass. , jan. 2, 2024 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled part c of the distinguish study evaluating dkn-01, leap's anti-dickkopf-1 (dkk1) antibody, in combination with tislelizumab, beigene's anti-pd-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer.
LPTX Ratings Summary
LPTX Quant Ranking